{"id":"heterologous-mrna-booster-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or swelling"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Fever"}]},"_chembl":{"chemblId":"CHEMBL2108573","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Heterologous boosting leverages cross-reactive T-cell and B-cell responses by administering an mRNA vaccine encoding antigens from a different but related pathogen or using a different mRNA platform after initial vaccination. This approach aims to broaden and strengthen adaptive immunity beyond what homologous boosting (same vaccine repeated) can achieve, potentially improving durability and breadth of protection.","oneSentence":"A heterologous mRNA booster vaccine uses messenger RNA from a different pathogen or platform to enhance immune response in individuals previously primed with another vaccine.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:23:00.111Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19 booster vaccination (heterologous prime-boost strategy)"}]},"trialDetails":[{"nctId":"NCT07408297","phase":"PHASE2","title":"Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda","status":"COMPLETED","sponsor":"Victoria Biomedical Research Institute","startDate":"2022-05-18","conditions":"COVID -19, SARS CoV 2 Infection","enrollment":1919},{"nctId":"NCT04889209","phase":"PHASE1, PHASE2","title":"Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-05-28","conditions":"COVID-19","enrollment":867},{"nctId":"NCT05925127","phase":"PHASE2, PHASE3","title":"Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines","status":"COMPLETED","sponsor":"Novavax","startDate":"2023-10-16","conditions":"COVID-19","enrollment":994},{"nctId":"NCT05142319","phase":"PHASE4","title":"Efficacy of Different COVID-19 Vaccine Combinations in Inducing Long-term Humoral Immunity [PRIBIVAC]","status":"COMPLETED","sponsor":"Tan Tock Seng Hospital","startDate":"2021-10-12","conditions":"COVID-19","enrollment":326},{"nctId":"NCT05593042","phase":"PHASE2","title":"Immunogenicity Evaluation of Omicron Variant-based Vaccine and a Trivalent Vaccine in Adults Against COVID-19 in Chile","status":"COMPLETED","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2022-11-28","conditions":"COVID-19, Vaccines","enrollment":551},{"nctId":"NCT04826770","phase":"","title":"Adaptive Immune Response to COVID-19 Vaccination","status":"UNKNOWN","sponsor":"University Medicine Greifswald","startDate":"2021-01-06","conditions":"SARS-CoV-2 Vaccination","enrollment":70},{"nctId":"NCT05609045","phase":"PHASE1","title":"A Phase 1, Randomised, Double-blinded, Placebo-controlled, Dose-escalation Study to Evaluate the Safety and Immunogenicity of RH109 as Booster","status":"WITHDRAWN","sponsor":"Wuhan Rhegen Biotechnology Co., Ltd.","startDate":"2023-06","conditions":"COVID-19 Pandemic","enrollment":""},{"nctId":"NCT05911087","phase":"PHASE2, PHASE3","title":"A Phase II/III Study to Evaluate the Immunogenicity and Safety and Efficacy of SWIM816 Vaccines for SARS-CoV-2","status":"UNKNOWN","sponsor":"Stemirna Therapeutics","startDate":"2023-06-20","conditions":"Immunogenicity, Safety","enrollment":800},{"nctId":"NCT05197153","phase":"PHASE2","title":"A Study to Evaluate the Safety and Immunogenicity of Booster With AZD1222, mRNA-1273, or MVC-COV1901 Against COVID-19","status":"COMPLETED","sponsor":"Medigen Vaccine Biologics Corp.","startDate":"2022-01-22","conditions":"COVID-19 Vaccine","enrollment":804},{"nctId":"NCT05175950","phase":"PHASE2","title":"Safety, Reactogenicity, and Immunogenicity Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510)","status":"UNKNOWN","sponsor":"Korea University Guro Hospital","startDate":"2022-01-24","conditions":"COVID-19 (Healthy Volunteers)","enrollment":770},{"nctId":"NCT05428592","phase":"PHASE3","title":"Clinical Trial of SARS-CoV-2 mRNA Vaccine(LVRNA009) as Heterologous Booster in Islamabad","status":"UNKNOWN","sponsor":"AIM Vaccine Co., Ltd.","startDate":"2023-04","conditions":"SARS-CoV-2","enrollment":1100},{"nctId":"NCT05686161","phase":"PHASE3","title":"mRNA Booster Vaccine(SW-BIC-213) Compared With Pfizer andSinopharm Against Emerging VOCs","status":"UNKNOWN","sponsor":"Stemirna Therapeutics","startDate":"2022-10-19","conditions":"Immunogenicity, Safety, Efficacy","enrollment":600},{"nctId":"NCT05081271","phase":"EARLY_PHASE1","title":"COVID-19 Booster Vaccination in Persons With Multiple Sclerosis","status":"TERMINATED","sponsor":"Griffin Hospital","startDate":"2021-10-15","conditions":"Multiple Sclerosis","enrollment":10},{"nctId":"NCT05492643","phase":"NA","title":"The Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (SYS6006) as Heterologous Booster in Participants Aged 18 Years and Older Vaccinated With Inactivated SARS-CoV-2 Vaccine","status":"UNKNOWN","sponsor":"Zhongnan Hospital","startDate":"2022-08-13","conditions":"SARS-CoV-2, Safety, Immunotoxicity","enrollment":1000},{"nctId":"NCT05547802","phase":"","title":"Serology After BBIBP-CorV Inactivated Vaccine Combined With BNT62b2 mRNA Booster Vaccine","status":"COMPLETED","sponsor":"University of Debrecen","startDate":"2021-11-16","conditions":"Basic BBIBP-CorV Vaccination is Not as Effective as BNT162b","enrollment":122},{"nctId":"NCT05132855","phase":"PHASE1, PHASE2","title":"The Immune Response of Heterologous Boost Third Dose of mRNA and Protein COVID-19 Vaccine","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2021-11-30","conditions":"COVID-19, Breakthrough Infection","enrollment":340},{"nctId":"NCT04569383","phase":"PHASE1","title":"Safety and Immunogenicity of the Candidate Vaccine MVA-SARS-2-S and a Booster Vaccination With a Licensed Vaccine Against COVID-19","status":"COMPLETED","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2020-10-05","conditions":"Covid19","enrollment":30},{"nctId":"NCT04993560","phase":"","title":"Safety and Efficacy of COVID-19 Prime-boost Vaccine in Bahrain","status":"COMPLETED","sponsor":"Royal College of Surgeons in Ireland - Medical University of Bahrain","startDate":"2021-07-18","conditions":"SARS-CoV 2 Infection, Covid19","enrollment":305}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Heterologous mRNA booster vaccine","genericName":"Heterologous mRNA booster vaccine","companyName":"Tan Tock Seng Hospital","companyId":"tan-tock-seng-hospital","modality":"Biologic","firstApprovalDate":"","aiSummary":"A heterologous mRNA booster vaccine uses messenger RNA from a different pathogen or platform to enhance immune response in individuals previously primed with another vaccine. Used for COVID-19 booster vaccination (heterologous prime-boost strategy).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}